Nasdaq FDA - Search News

FDA Approves 1st Non-Opioid Pain Drug in 20 Years

FDA approves Vertex's first-in-class non-opioid analgesic for acute pain

Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug is a non-opioid analgesic,

Wall Street Journal · 5h

First New Non-Opioid Painkiller in Decades Gets FDA Approval

Vertex Pharmaceuticals won U.S. approval for the first new non-opioid painkiller in decades, which could be a blockbuster if the company can persuade insurers and doctors to embrace the non-addictive alternative to notorious drugs like OxyContin.

Eagle-Tribune · 6h

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain.

Axsome, FDA and migraine

Hosted on MSN · 7h

Axsome gets FDA approval for Symbravo for migraine

Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or without aura in adults. Symbravo, a combination of meloxicam and rizatriptan,

Reuters on MSN · 5h

US FDA approves Axsome Therapeutics' migraine drug

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday. The oral drug, branded Symbravo, was approved for the acute treatment of the condition characterized by recurrent attacks of moderate to severe throbbing and pulsating pain on one side of the head.

Business Insider · 8h

Axsome Therapeutics announces FDA approval of Symbravo

Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in

Biotech Stocks Facing FDA Decision In February 2025

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

6don MSN

2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...

3don MSN

Atara to cut 50% of workforce amid FDA woes

Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after it said the FDA had declined to approve its immunotherapy Ebvallo. The ...

Merck: FDA grants priority review to sNDA for Welireg

Merck (MRK) announced the U.S. FDA has accepted for priority review a supplemental new drug application seeking approval of Welireg, Merck’s ...

3don MSN

Vanda Pharmaceuticals seeks FDA nod for motion sickness drug

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed through a social media post ...

3don MSN

FDA accepts Teva, Alvotech BLAs for Simponi biosimilars

Biologics License Applications for AVT05, their proposed biosimilar to the anti-inflammatory drugs Simponi and Simponi Aria. Review of the applications is expected to by completed in Q4 2025, ...

Strong Outlook for Cartesian Therapeutics: FDA SPA Agreement and Positive Phase 2b Results Boost Confidence in Descartes-08

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated ...

3don MSN

Why Mesoblast (MESO) Is Among the Best Australian Stocks to Buy Now?

We recently compiled a list of the 10 Best Australian Stocks to Buy Now. In this article, we are going to take a look at ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results